Our Services
Medical Information
Helpful Resources
Published on: 7/21/2026
Fatigue on GLP-1 therapy is commonly caused by low sodium and potassium levels. These electrolytes are depleted through gastrointestinal side effects like nausea, vomiting, and diarrhea, as well as reduced food and fluid intake. Since sodium and potassium regulate fluid balance, nerve signaling, and muscle function, low levels directly drain your energy.
Key factors to manage electrolytes on GLP-1s include:
Because fatigue can also signal other underlying conditions, it's important not to guess. Understanding whether your symptoms stem from electrolyte depletion, medication dosage, or something else entirely is the first step toward feeling better. Take a free, instant, online symptom check to clarify what's driving your fatigue and get personalized guidance on your next steps.
Reviewed for medical accuracy: 07/21/2026
If you're taking a GLP-1 agonist (like semaglutide or liraglutide) to manage weight or blood sugar, you may notice lower energy levels or feeling "drained." While these medications can be life-changing, they may also cause gastrointestinal side effects and changes in fluid balance that can deplete key electrolytes—especially sodium and potassium. Understanding how these minerals support your body can help you stay energized and healthy.
GLP-1 (glucagon-like peptide-1) agonists mimic a natural hormone that:
These effects can lead to weight loss and improved blood sugar control, but they can also:
When fluid intake falls or GI losses rise, you risk electrolyte imbalances. The most critical minerals to monitor are sodium and potassium—both essential for energy, muscle function, and overall well-being.
Sodium is often criticized for its role in high blood pressure, but it's vital in moderate amounts for:
When sodium drops too low (hyponatremia), you might experience:
Potassium works closely with sodium. Its main roles include:
Low potassium (hypokalemia) can lead to:
Watch for these common clues that sodium or potassium might be low:
If you notice any of these symptoms and want immediate guidance, try our Medically approved LLM Symptom Checker Chat Bot to help determine whether you need urgent care or can manage at home.
Hydrate Smartly
Incorporate Electrolyte-Rich Foods
Balance Your Meals
Monitor Portion Sizes
Track Your Symptoms
Consider a Supplement (If Recommended)
Electrolyte imbalances can escalate quickly if left unchecked. Contact your healthcare provider or head to the ER immediately if you experience:
For less urgent concerns, schedule an appointment or consult with our free Medically approved LLM Symptom Checker Chat Bot to get personalized recommendations based on your specific symptoms.
Everyone's body reacts differently to GLP-1 therapy. Your age, kidney function, baseline blood pressure and other medications can all influence how your sodium and potassium levels change. Only a qualified healthcare professional can:
Your energy and safety matter. With a little planning around sodium and potassium, you'll be better equipped to enjoy the benefits of your GLP-1 therapy without feeling drained. If you ever feel something is seriously off, please speak to a doctor right away.
(References)
* Nanduri S, Panta P, Saravu K. Dehydration and Acute Kidney Injury Associated With Glucagon-Like Peptide-1 Receptor Agonists and Glucose-Dependent Insulinotropic Polypeptide Receptor Agonists: A Disproportionality Analysis of the FDA Adverse Event Reporting System (FAERS). J Clin Endocrinol Metab. 2024 Apr 19;109(5):e2089-e2098. doi: 10.1210/clinem/dgad811. PMID: 38048123.
* Sun F, Lu Y, Cai R, Li L, Yang Z, Zhu J, Luo R, Wu J, Wang H. Gastrointestinal Adverse Events with Glucagon-like Peptide-1 Receptor Agonists: A Systematic Review and Meta-Analysis. Front Endocrinol (Lausanne). 2021 Jul 2;12:683424. doi: 10.3389/fendo.2021.683424. PMID: 34276592; PMCID: PMC8284521.
* Rana A, Li L, Kim SC, Choudhry NK, Lii J, Desai RJ. Risk of electrolyte disturbances with glucagon-like peptide-1 receptor agonists: a population-based cohort study. Pharmacoepidemiol Drug Saf. 2023 Nov;32(11):1323-1331. doi: 10.1002/pds.5670. Epub 2023 Aug 17. PMID: 37592477.
* Wilding JPH, Batterham RL, Blickwede M, et al. Management of gastrointestinal adverse events associated with glucagon-like peptide-1 receptor agonists: a consensus statement. Lancet Diabetes Endocrinol. 2022 Dec;10(12):873-888. doi: 10.1016/S2213-8587(22)00262-6. Epub 2022 Nov 3. PMID: 36334524.
* Mani A, Ahmad MS, Shaikh MF, et al. Adverse Drug Reactions of GLP-1 Receptor Agonists. Curr Drug Saf. 2024;19(1):47-56. doi: 10.2174/1574886319666240105151608. PMID: 38180907.
We would love to help them too.
For First Time Users
We provide a database of explanations from real doctors on a range of medical topics. Get started by exploring our library of questions and topics you want to learn more about.
Was this page helpful?
Purpose and positioning of servicesUbie Doctor's Note is a service for informational purposes. The provision of information by physicians, medical professionals, etc. is not a medical treatment. If medical treatment is required, please consult your doctor or medical institution. We strive to provide reliable and accurate information, but we do not guarantee the completeness of the content. If you find any errors in the information, please contact us.